It sounds like a potential money-maker...Lannett® Company, Inc. (Amex: LCI - News) is delighted to announce that Jerome Stevens Pharmaceutical, Inc. (JSP), Lannett's exclusive supplier, has received a letter from the Food and Drug Administration (FDA) approving the bioequivalence of its Levothyroxine Sodium Tablet to Synthroid®, which is marketed by Abbott Laboratories Inc.Levothyroxine Sodium Tablets are used to treat hypothyroidism and other thyroid disorders. It is one of the most prescribed drugs in the United States with over 13 million patients. According to market research, the annual retail sales for Synthroid® are approximately $800 million.full story:http://biz.yahoo.com/prnews/041214/detu020_1.html
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat